Neurogene's One-Time Gene Therapy NGN-401 Receives FDA Breakthrough Nod

Neurogene’s NGN-401 gene therapy just received FDA Breakthrough Therapy Designation for Rett syndrome. Early trial results show lasting improvements in skills and daily life.